Posted by Michael Wonder on 02 Apr 2026
Eylea HD (aflibercept) approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months for wet age-related macular degeneration and diabetic macular oedema
2 April 2026 - Regeneron Pharmaceuticals today announced that the US FDA has approved the extension of dosing intervals for EYlea HD (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneration and diabetic macular oedema following one year of successful response based on visual and anatomic outcomes.
As part of the approval, the FDA has updated the EYLEA HD label to include 96 week (2 year) data from the pivotal PULSAR trial in wet age-related macular degeneration and the pivotal PHOTON trial in diabetes macular oedema, demonstrating sustained efficacy and safety through 2 years with extended dosing intervals.
